FindTrial
Sign In

A multicenter study to predict TP53 gene mutation status in non-small cell lung cancer based on hematoxylin and eosin (HE) Images and P53 immunohistochemistry images

A multicenter study to predict TP53 gene mutation status in non-small cell lung cancer based on hematoxylin and eosin (HE) Images and P53 immunohistochemistry images

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094997
Enrollment
Unknown
Registered
2024-12-31
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Gold Standard:Using the gene sequencing results of non-small cell lung cancer as the gold standard.
Index test:Using hematoxylin and eosin (HE) Images and P53 immunohistochemistry images of non-small cell lung cancer to predicte TP53 gene mutation status.

Sponsors

The First Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Cases with pathological diagnoses of non-small cell lung cancer; 2.Cases with P53 immunohistochemistry results; 3.Cases with gene sequencing results;

Exclusion criteria

Exclusion criteria: 1.Metastatic tumors; 2.Cases with suboptimal pathological slide quality;

Design outcomes

Primary

MeasureTime frame
TP53 mutation status;Accuracy;Sensitivity;Specificity;—

Secondary

MeasureTime frame
Positive predicative value;Negative predictive value;—

Countries

China

Contacts

Public ContactCao Mian-Fu

The First Affiliated Hospital of Army Medical University

396739732@qq.com+86 15922984987

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026